Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

Table 1 In vivo antibody PK and in vitro biacore binding properties

Molecule	Dose (i.v.)mg/kg	Isotype	C_max(μg/ml)	AUC_last(μg/ml day)	CL_obs(ml/day/kg)	Biacore monomericAβ Kd (nM)	Biacore oligomericAβ Kd (nM)
Crenezumab	20	hIgG4	296	882	19.6	5	0.5
Anti-moAβ [23]	20	hIgG1	319	113	176.4	0.2	Not detected
Anti-gD	20	hIgG1	410	1457	7.6	–	–

PK pharmacokinetics, i.v. intravenous, C_max maximum concentration, AUC_last area under the curve from the time of last dosing to the last measurable concentration, CL_obs total body clearance, Aβ amyloid β, hIgG humanized immunoglobulin G, moAβ monomeric amyloid β, gD glycoprotein D

ISSN: 1758-9193